Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Pembrolizumab in Recurrent PTCL
NCT04795869Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Mar 2020
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in peripheral T-cell lymphoma (PTCL), sponsored by Northwestern University. Planned start Mar 2020; status: withdrawn.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04795869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795869.